RESECT has recently published its inaugural paper, led by the Department of Thoracic Surgery at Dr. Balmis University Hospital in Alicante. The study, entitled ‘Neoadjuvant chemoinmunotherapy in resected stage III non-small-cell lung cancer: real-world data from a nationwide registry,’ has been published open access in Translational Lung Cancer Research (Impact Factor: 3.4).
This research addresses a highly relevant and timely topic in lung cancer management, establishing an exceptional foundation for the future scientific output of our registry.
